Clinical Trials on Astrocytoma, IDH-Mutant, Grade 2

Total 484 results

National Cancer Institute (NCI)

Active, not recruiting

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

Astrocytoma, IDH-Mutant, Grade 2 | Astrocytoma, IDH-Mutant, Grade 3

United States
Juan M Garcia-Gomez
Hospital Universitario 12 de Octubre; Hospital Clínico Universitario de Valencia

Recruiting

BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and Histopathological Levels (BIOhabitats)

Glioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Mutant

Spain
National Cancer Institute (NCI)

Suspended

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden

Diffuse Glioma | Secondary Glioblastoma | Glioblastoma, IDH-Wildtype | Astrocytoma, IDH-Mutant, Grade 4

United States, Puerto Rico
Jasper Gerritsen
Massachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaborators

Recruiting

The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201) (SUPRAMAX)

Glioblastoma | Brain Neoplasms | Astrocytoma, Grade III | High-grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Brain Neoplasm, Primary | Brain Neoplasm, Malignant | Astrocytoma, Malignant | Brain Neoplasms, Adult

United States, Germany, Belgium, Switzerland, Netherlands
Rigel Pharmaceuticals
Nationwide Children's Hospital

Not yet recruiting

Study of Olutasidenib and Temozolomide in HGG

Astrocytoma | High Grade Glioma | Oligodendroglioma | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | WHO Grade III Glioma | Metastatic Brain Tumor | Spinal Tumor | Astrocytoma, Grade III | Astrocytoma, Grade IV | IDH1 Mutation | WHO Grade IV Glioma | Thalamus Tumor | IDH1 R132 | IDH1 R132C | IDH1 R132H and other conditions

United States, Australia, United Kingdom, Canada, Germany, Netherlands
M.D. Anderson Cancer Center

Recruiting

Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas

Glioblastoma | Anaplastic Oligoastrocytoma | Oligoastrocytoma | Oligodendroglioma | Anaplastic Oligodendroglioma | WHO Grade III Glioma | Diffuse Astrocytoma, IDH-Wildtype | WHO Grade II Glioma | Anaplastic Astrocytoma, IDH-Wildtype

United States
Oslo University Hospital
Karolinska University Hospital; University Hospital of North Norway; Sahlgrenska... and other collaborators

Recruiting

PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas (PRO-GLIO)

Oligodendroglioma | Oligodendroglioma, Anaplastic | Diffuse Astrocytoma, IDH-Mutant

Norway
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma

Glioma | Oligoastrocytoma | Anaplastic Astrocytoma | Oligodendroglioma | Diffuse Astrocytoma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | 1p/19q Co-deletion

United States
Sunnybrook Health Sciences Centre

Recruiting

UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly (UNITED2)

Glioblastoma, IDH-mutant | Glioblastoma Multiforme, Adult

Canada
Northwestern University
National Cancer Institute (NCI); BrainUp Inc

Not yet recruiting

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

Recurrent WHO Grade 2 Glioma | Recurrent Glioblastoma, IDH-Wildtype | Recurrent WHO Grade 3 Glioma | Recurrent WHO Grade 4 Glioma

United States
Samus Therapeutics, Inc.

Terminated

Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma (Glio)

Recurrent Glioblastoma Multiforme (GBM) | Grade 3 Isocitrate Dehydrogenase (IDH) Wildtype Astrocytoma | Grade 3 or 4 Astrocytoma | Glioblastoma Surgery

United States
National Cancer Institute (NCI)

Recruiting

Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

Recurrent WHO Grade 2 Glioma | Recurrent Glioblastoma, IDH-Wildtype | Recurrent WHO Grade 3 Glioma

United States
University of California, San Francisco
BeiGene USA, Inc.; Pacific Pediatric Neuro-Oncology Consortium

Recruiting

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (PNOC017)

Glioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | Low Grade Glioma | Recurrent WHO Grade II Glioma | WHO Grade II Glioma

United States
Debiopharm International SA

Recruiting

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Astrocytoma, Grade III | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Spain, United States, Switzerland
Hospices Civils de Lyon

Completed

Olaparib in Recurrent IDH-mutant Glioma (OLAGLI)

Recurrent IDH | Mutant High Grade Glioma

France
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); BeiGene

Completed

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | IDH1 Mutation | IDH2 Mutation

United States
National Cancer Institute (NCI)

Recruiting

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

Recurrent WHO Grade 2 Glioma | Recurrent Low Grade Astrocytoma | Refractory Low Grade Astrocytoma | Refractory Low Grade Glioma | Refractory WHO Grade 1 Glioma

United States, Canada
University of California, San Francisco
Novartis

Terminated

Everolimus With and Without Temozolomide in Adult Low Grade Glioma

Low Grade Glioma | World Health Organization (WHO) Grade II Astrocytomas | Oligodendrogliomas | Mixed Oligoastrocytomas

United States
Washington University School of Medicine

Completed

Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma

Astrocytoma, Grade III | Astrocytoma, Grade IV | Grade IV Astrocytoma | Grade III Astrocytoma

United States
Memorial Sloan Kettering Cancer Center
Agios Pharmaceuticals, Inc.

Recruiting

AG-120 in People With IDH1 Mutant Chondrosarcoma

Chondrosarcoma | IDH1 Gene Mutation | Chondrosarcoma, Grade 2 | Chondrosarcoma, Grade 3

United States
Nationwide Children's Hospital
Novartis

Not yet recruiting

Study of Ribociclib and Everolimus in HGG and DIPG

Glioblastoma | Glioblastoma Multiforme | High Grade Glioma | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | WHO Grade III Glioma | Metastatic Brain Tumor | WHO Grade IV Glioma

United States, Australia, United Kingdom, Canada, Germany, Netherlands
Nationwide Children's Hospital

Not yet recruiting

Targeted Pediatric High-Grade Glioma Therapy

Glioblastoma | Glioblastoma Multiforme | High Grade Glioma | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | WHO Grade III Glioma | Metastatic Brain Tumor | WHO Grade IV Glioma

United States, Australia, United Kingdom, Canada, Germany, Netherlands
Servier Bio-Innovation LLC
Institut de Recherches Internationales Servier

Recruiting

Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma

IDH1-mutant Cholangiocarcinoma

United States, United Kingdom
National Cancer Institute (NCI)

Recruiting

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

Low Grade Glioma | Low Grade Astrocytoma | Metastatic Low Grade Astrocytoma | Metastatic Low Grade Glioma

United States, Canada, Puerto Rico
University of Florida
NovoCure Ltd.

Terminated

FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma (FORWARD)

Astrocytoma, Grade III | Astrocytoma, Grade II

United States
Orbus Therapeutics, Inc.

Recruiting

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma

Glioblastoma | Glioblastoma Multiforme | GBM | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

United States
St. Jude Children's Research Hospital
Novartis Pharmaceuticals

Active, not recruiting

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Glioma | Neoplasms | Glioblastoma | Neoplasms, Neuroepithelial | Central Nervous System Neoplasms | Brain Cancer | Brain Tumor | Ependymoma | Medulloblastoma | Anaplastic Astrocytoma | Anaplastic Ganglioglioma | Anaplastic Ependymoma | Anaplastic Oligodendroglioma | Pineoblastoma | Recurrent Medulloblastoma | CNS Tumor | Pediatric... and other conditions

United States
Erasmus Medical Center
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Leiden University... and other collaborators

Recruiting

Radiotherapy in IDH Mutated Glioma: Evaluation of Late Outcomes (RIGEL)

Oligodendroglioma | Astrocytoma, Grade III | Astrocytoma, Grade II | Oligodendroglioma, Anaplastic

Netherlands
National Cancer Institute (NCI)

Completed

Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma

Glioma | Glioblastoma Multiforme | Giant Cell Glioblastoma | Oligodendrogliomas | Astrocytoma, Grades II, III and IV

United States
Northwell Health

Withdrawn

Study of Stereotactic Radiosurgery to the Subventricular Zone in Malignant Gliomas

Glioblastoma | Malignant Glioma | Astrocytoma, Grade III | Astrocytoma, Grade IV

United States
Stony Brook University
Garnett McKeen Laboratory Inc.

Completed

Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA (DESSTINI_A)

Glioblastoma Multiform (Grade IV Astrocytoma)

United States
Mayo Clinic
Merck Sharp & Dohme LLC; NeoImmune Tech

Recruiting

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Recurrent Glioblastoma, IDH-Wildtype | Recurrent Gliosarcoma | High Grade Astrocytic Tumor

United States
National Cancer Institute (NCI)

Completed

Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy

Childhood High-grade Cerebellar Astrocytoma | Childhood High-grade Cerebral Astrocytoma | Recurrent Childhood Anaplastic Astrocytoma | Recurrent Childhood Anaplastic Oligoastrocytoma | Recurrent Childhood Anaplastic Oligodendroglioma | Recurrent Childhood Cerebellar Astrocytoma | Recurrent Childhood... and other conditions

United States, Canada
Burzynski Research Institute

Completed

Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma

Low Grade Astrocytomas

United States
BioMimetix JV, LLC
National Cancer Institute (NCI); Duke Cancer Institute

Active, not recruiting

Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 (BMX-HGG)

Glioblastoma | High Grade Glioma | Astrocytoma, Grade III

United States
Children's Hospital Medical Center, Cincinnati

Terminated

Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy

Glioblastoma Multiforme (WHO Grade IV) | Anaplastic Astrocytoma (WHO Grade III)

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

Recurrent Glioblastoma | Diffuse Astrocytoma, IDH-Wildtype

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

Recurrent Glioblastoma | IDH Family Wildtype | Recurrent Anaplastic Astrocytoma

United States
The University of Texas Health Science Center at...

Completed

Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab

HIGH GRADE GLIOMA

United States
National Cancer Institute (NCI)

Completed

Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors

Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Childhood Choroid Plexus Tumor | Childhood Craniopharyngioma | Childhood Ependymoblastoma | Childhood Grade I Meningioma | Childhood Grade II Meningioma | Childhood Grade III Meningioma | Childhood High-grade Cerebellar Astrocytoma | Childhood High-grade Cerebral Astrocytoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors

Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Childhood Atypical Teratoid/Rhabdoid Tumor | Childhood Choroid Plexus Tumor | Childhood Craniopharyngioma | Childhood Ependymoblastoma | Childhood Grade I Meningioma | Childhood Grade II Meningioma | Childhood Grade III Meningioma | Childhood High-grade Cerebellar Astrocytoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Cilengitide in Treating Children With Refractory Primary Brain Tumors

Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Childhood Choroid Plexus Tumor | Childhood Craniopharyngioma | Childhood Ependymoblastoma | Childhood Grade I Meningioma | Childhood Grade II Meningioma | Childhood Grade III Meningioma | Childhood High-grade Cerebellar Astrocytoma | Childhood High-grade Cerebral Astrocytoma and other conditions

United States
The University of Tennessee, Knoxville

Completed

Evaluating Feasibility and Effectiveness of Computerized Mathematic Training

Math Teachers (Grades 2-8) | Math Students (Grades 2-8)

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma

Ann Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann... and other conditions

United States
Maastricht Radiation Oncology
Maastricht University Medical Center

Terminated

Positron Emission Tomography-Computed Tomography (PET-CT) High-grade Glioma

Cerebral Astrocytoma, High Grade

Netherlands
Shuttle Pharmaceuticals, Inc.

Not yet recruiting

Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

Glioblastoma, IDH-wildtype

United States
European Organisation for Research and Treatment...
Tragara Pharmaceuticals, Inc.

Completed

Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma (STEAM)

Glioblastoma | Astrocytoma, Grade III

France, Austria, Germany, Netherlands, Switzerland
Tianjin Medical University General Hospital

Recruiting

Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma

Glioblastoma, IDH-wildtype

China
Peking Union Medical College Hospital

Not yet recruiting

Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma

Glioblastoma, IDH-wildtype

China
Massachusetts General Hospital
GlaxoSmithKline

Recruiting

Niraparib In Recurrent IDH 1/2 Gliomas

Recurrent Glioma | Low-grade Glioma | Glioma, Malignant | IDH2 Gene Mutation | IDH1 Mutation

United States

Clinical Trials on Astrocytoma, IDH-Mutant, Grade 2

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations